Skin Blood Clots in a Patient with Factor V Leiden
Author Information
Author(s): Muacevic Alexander, Adler John R, Nardella Francis A
Primary Institution: St. Luke’s Meridian Medical Center
Hypothesis
Can a patient with Factor V Leiden heterozygosity and noncriteria antiphospholipid antibodies develop recurrent cutaneous microthrombosis?
Conclusion
The patient showed improvement with rituximab and apixaban, leading to the normalization of antibody levels and cessation of skin blood clot events.
Supporting Evidence
- The patient had recurrent cutaneous microthrombosis despite negative tests for criteria antiphospholipid antibodies.
- Treatment with rituximab led to normalization of antibody levels.
- The patient was stable off of prednisone at her last visit.
Takeaway
A woman with a specific genetic condition had skin blood clots, but after treatment, her condition got better and she stopped needing some medications.
Methodology
The patient was treated with prednisone, apixaban, and rituximab, and her condition was monitored over 22 months.
Potential Biases
Potential bias due to the lack of a control group and reliance on a single patient's data.
Limitations
The study is based on a single case report, limiting generalizability.
Participant Demographics
30-year-old woman with a history of inflammatory bowel disease.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website